USD 0.02
(3.88%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 465.73 Thousand USD | -16.25% |
2022 | 556.11 Thousand USD | 3.88% |
2021 | 535.34 Thousand USD | 6.47% |
2020 | 502.79 Thousand USD | 11.15% |
2019 | 452.34 Thousand USD | 7.05% |
2018 | 422.54 Thousand USD | -74.51% |
2017 | 1.65 Million USD | 0.0% |
2015 | 771.65 Thousand USD | -2.72% |
2014 | 793.23 Thousand USD | 113442.72% |
2013 | 698.62 USD | 0.0% |
2009 | 1.45 Million USD | -0.61% |
2008 | 1.46 Million USD | 5.19% |
2007 | 1.39 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 433.52 Thousand USD | -1.63% |
2024 Q1 | 440.69 Thousand USD | -5.38% |
2023 Q4 | 465.73 Thousand USD | -3.39% |
2023 Q2 | 564.24 Thousand USD | 1.03% |
2023 Q1 | 558.51 Thousand USD | 0.43% |
2023 FY | 465.73 Thousand USD | -16.25% |
2023 Q3 | 482.08 Thousand USD | -14.56% |
2022 Q1 | 539.96 Thousand USD | 0.86% |
2022 Q2 | 547.81 Thousand USD | 1.45% |
2022 Q3 | 548.96 Thousand USD | 0.21% |
2022 FY | 556.11 Thousand USD | 3.88% |
2022 Q4 | 556.11 Thousand USD | 1.3% |
2021 Q3 | 529.48 Thousand USD | 0.66% |
2021 FY | 535.34 Thousand USD | 6.47% |
2021 Q2 | 526 Thousand USD | -5.94% |
2021 Q1 | 559.22 Thousand USD | 0.0% |
2021 Q4 | 535.34 Thousand USD | 1.11% |
2020 FY | 502.79 Thousand USD | 11.15% |
2019 FY | 452.34 Thousand USD | 7.05% |
2018 FY | 422.54 Thousand USD | -74.51% |
2017 FY | 1.65 Million USD | 0.0% |
2015 FY | 771.65 Thousand USD | -2.72% |
2014 Q4 | 793.23 USD | 0.78% |
2014 Q2 | 770.96 USD | 4.32% |
2014 FY | 793.23 Thousand USD | 113442.72% |
2014 Q1 | 739.03 USD | 5.78% |
2014 Q3 | 787.06 USD | 2.09% |
2013 Q4 | 698.62 USD | -18.9% |
2013 FY | 698.62 USD | 0.0% |
2013 Q3 | 861.40 USD | 10.43% |
2013 Q1 | 2291.74 USD | 0.0% |
2013 Q2 | 780.01 USD | -65.96% |
2010 Q2 | 1.47 Million USD | 0.02% |
2010 Q1 | 1.47 Million USD | 1.33% |
2010 Q3 | 1.52 Million USD | 3.39% |
2009 Q2 | 1.46 Million USD | 0.0% |
2009 Q1 | 1.46 Million USD | 0.0% |
2009 FY | 1.45 Million USD | -0.61% |
2009 Q4 | 1.45 Million USD | -0.17% |
2009 Q3 | 1.46 Million USD | -0.2% |
2008 FY | 1.46 Million USD | 5.19% |
2007 FY | 1.39 Million USD | 0.0% |
2007 Q1 | 860.93 Thousand USD | 0.0% |
2007 Q2 | 1.26 Million USD | 46.75% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
China Medicine Corporation | 21.33 Million USD | 97.817% |
DH Enchantment Inc. | 989.77 Thousand USD | 52.945% |
Exlites Holdings International, Inc. | 33.75 Thousand USD | -1279.918% |
Itonis, Inc. | 1.14 Million USD | 59.398% |
MediPal Holdings Corporation | 7.02 Billion USD | 99.993% |
PD-Rx Pharmaceuticals, Inc. | 1.69 Million USD | 72.559% |
Pharmagen, Inc. | 8868.81 USD | -5151.392% |
Suzuken Co., Ltd. | 5.36 Billion USD | 99.991% |